Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial

•In this sub-analysis of the ENGAGE AF-TIMI 48 trial patients with diabetes were more prone to bleeding.•The approved edoxaban regimen reduced major bleeding and CV death, while achieving similar protection from thromboembolism.•The pharmacokinetic and pharmacodynamic results of edoxaban were consistent regardless of the diabetes status.